Management of axillary disease

Abigail S. Caudle; Julie A. Cupp; Henry M. Kuerer

doi:10.1016/j.soc.2014.03.007

Management of axillary disease

Abigail S. Caudle, Julie A. Cupp, Henry M. Kuerer

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently recommended to undergo ALND, although these recommendations may change with emerging trial data.

Original language	English (US)
Pages (from-to)	473-486
Number of pages	14
Journal	Surgical oncology clinics of North America
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.soc.2014.03.007
State	Published - Jul 2014

Keywords

Axillary lymphadenectomy
Breast cancer
Neoadjuvant chemotherapy
Nodal metastasis
Sentinel lymph node

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2014.03.007

Cite this

@article{69a9cd3ee0cd4a42b59b6c346b686874,

title = "Management of axillary disease",

abstract = "The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently recommended to undergo ALND, although these recommendations may change with emerging trial data.",

keywords = "Axillary lymphadenectomy, Breast cancer, Neoadjuvant chemotherapy, Nodal metastasis, Sentinel lymph node",

author = "Caudle, {Abigail S.} and Cupp, {Julie A.} and Kuerer, {Henry M.}",

year = "2014",

month = jul,

doi = "10.1016/j.soc.2014.03.007",

language = "English (US)",

volume = "23",

pages = "473--486",

journal = "Surgical oncology clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Management of axillary disease

AU - Caudle, Abigail S.

AU - Cupp, Julie A.

AU - Kuerer, Henry M.

PY - 2014/7

Y1 - 2014/7

N2 - The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently recommended to undergo ALND, although these recommendations may change with emerging trial data.

AB - The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently recommended to undergo ALND, although these recommendations may change with emerging trial data.

KW - Axillary lymphadenectomy

KW - Breast cancer

KW - Neoadjuvant chemotherapy

KW - Nodal metastasis

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=84901652459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901652459&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2014.03.007

DO - 10.1016/j.soc.2014.03.007

M3 - Review article

C2 - 24882346

AN - SCOPUS:84901652459

SN - 1055-3207

VL - 23

SP - 473

EP - 486

JO - Surgical oncology clinics of North America

JF - Surgical oncology clinics of North America

IS - 3

ER -

Management of axillary disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this